Wesley R Anderson
Affiliations: | 1988 | University of Florida, Gainesville, Gainesville, FL, United States |
Google:
"Wesley Anderson"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Brewster ME, Anderson WR, Meinsma D, et al. (1997) Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. Journal of Pharmaceutical Sciences. 86: 335-9 |
| Brewster ME, Anderson WR, Pop E. (1997) Effect of sustained estradiol release in the intact male rat: correlation of estradiol serum levels with actions on body weight, serum testosterone, and peripheral androgen-dependent tissues. Physiology & Behavior. 61: 225-9 |
| Brewster ME, Anderson WR, Webb AI, et al. (1997) Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrobial Agents and Chemotherapy. 41: 122-8 |
| Pop E, Soti F, Anderson WR, et al. (1996) Redox targeting of LY231617, an antioxidant with potential use in the treatment of brain damage International Journal of Pharmaceutics. 140: 33-44 |
| Brewster ME, Anderson WR, Loftsson T, et al. (1995) Preparation, characterization, and anesthetic properties of 2-hydroxypropyl-beta-cyclodextrin complexes of pregnanolone and pregnenolone in rat and mouse. Journal of Pharmaceutical Sciences. 84: 1154-9 |
| Brewster ME, Druzgala PJ, Anderson WR, et al. (1995) Efficacy of a 3-substituted versus 17-substituted chemical delivery system for estradiol brain targeting. Journal of Pharmaceutical Sciences. 84: 38-43 |
| Brewster ME, Anderson WR, Estes KS, et al. (1995) Tissue distribution of LY231617, an antioxidant with neuroprotectant activity, in the rat. Journal of Pharmaceutical Sciences. 84: 791-3 |
| Brewster ME, Anderson WR, Helton DO, et al. (1995) Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system. Pharmaceutical Research. 12: 796-8 |
| Amselem S, Friedman D, Yogev A, et al. (1995) Formulation development for a zidovudine chemical delivery system 2. Towards oral and non-parenteral dosage forms International Journal of Pharmaceutics. 125: 31-43 |
| Brewster ME, Loftsson T, Amselem S, et al. (1995) Formulation development for a zidovudine chemical delivery system 1. Parenteral dosage forms International Journal of Pharmaceutics. 125: 17-30 |